Related Experiment Video
Updated: May 4, 2026
10:13
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
11.3K
Targeting KRAS in colorectal cancer (Review)
Minjie Zhang1, Dawei Wu2, Yu Tang2
1Clinical Trials Center, Luanzhou People's Hospital, Tangshan, Hebei 063700, P.R. China.
Molecular and Clinical Oncology
|July 22, 2025
Summary
RAS mutations drive cancer progression, particularly in colorectal cancer. Combining KRAS G12C inhibitors with EGFR antibodies shows promise, overcoming resistance and improving treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- RAS genes regulate cell growth, differentiation, and apoptosis.
- Mutated RAS genes, especially KRAS, are oncogenic drivers in various cancers.
- KRAS mutations are common in colorectal cancer (CRC), correlating with poor prognosis.
Purpose of the Study:
- To investigate the role of KRAS mutations in colorectal cancer progression.
- To evaluate the efficacy of KRAS G12C inhibitors in CRC.
- To explore the potential of combination therapies involving KRAS inhibitors and EGFR antibodies.
Main Methods:
- Analysis of KRAS mutation status in colorectal cancer patient cohorts.
- Assessment of KRAS G12C inhibitor monotherapy efficacy.
- Evaluation of combination regimens with KRAS G12C inhibitors and EGFR monoclonal antibodies (e.g., cetuximab).
Main Results:
- KRAS mutations are complex oncogenic drivers in CRC, linked to poor outcomes.
- KRAS G12C inhibitor monotherapy shows limited efficacy in CRC due to resistance.
- Combination therapy with KRAS G12C inhibitors and EGFR antibodies significantly improved objective response rates.
Conclusions:
- KRAS mutations present a significant challenge in colorectal cancer treatment.
- Monotherapy with KRAS G12C inhibitors is insufficient for effective CRC treatment.
- Combining KRAS G12C inhibitors with EGFR antibodies offers synergistic therapeutic potential for KRAS-mutated CRC.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.9K
06:19Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
Published on: July 18, 2017
10.2K
Related Concept Videos
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
02:38The Ras Gene
5.7K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
5.7K
03:03mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:24Small GTPases - Ras and Rho
4.4K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.4K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81